Key result
Long-chain fatty acid oxidation disorders show specific cytokine and monocyte changes without major inflammatory differences.
Why the study?
The rewiring of fatty acid oxidation and the effect of inherited long-chain fatty acid oxidation disorders on human monocyte and macrophage phenotype and function remain largely unknown.
Do monocytes and macrophages from patients with lcFAOD show inflammatory or metabolic differences compared to healthy controls?
Case-Control (n=22)
Do monocytes and macrophages from patients with lcFAOD show inflammatory or metabolic differences compared to healthy controls?
Monocytes and macrophages from lcFAOD patients present no major inflammatory or metabolic differences but show that IL-4-induced surface markers are intertwined with long-chain fatty acid oxidation in human macrophages.
No major monocyte differences in lcFAOD; leaves open IL-4 pathway roles for targeted mechanistic studies.
Patients with inherited disorders of the long-chain fatty acid oxidation (lcFAO) machinery present with a heterogeneous profile of disease manifestations and aggravation of symptoms is often triggered by inflammatory activation. Monocytes and macrophages are innate immune cells that play a major role in the onset and resolution of inflammation. These cells undergo metabolic rewiring upon activation including the regulation of the FAO rate. The rewiring of FAO and the effect of lcFAO disorders (lcFAOD) on human monocyte and macrophage phenotype and function remain largely unknown. Here, we performed extensive phenotyping of circulating monocytes and analyzed plasma cytokine levels in 11 lcFAOD patients and 11 matched control subjects. In patients with lcFAOD, we observed induced plasma levels of the inflammatory cytokines IL-1β and IL-6, and enhanced CD206 and CD62L surface marker expression in circulating monocyte subsets. To mimic the most common lcFAOD very-long-chain acyl-CoA dehydrogenase disorder (VLCADD), we used siRNA-mediated knockdown of the ACADVL gene (encoding VLCAD) in macrophages derived from healthy volunteers. Hereby, we found that siVLCAD affected IL-4-induced alternative macrophage activation while leaving LPS responses and cellular metabolism intact. In the same line, monocyte-derived macrophages from lcFAOD patients had elevated levels of the IL-4-induced alternative macrophage markers CD206 and CD200R. Still, they did not show major metabolic defects or changes in the LPS-induced inflammatory response. Our results indicate that monocytes and macrophages from lcFAOD patients present no major inflammatory or metabolic differences and show that IL-4-induced surface markers are intertwined with lcFAO in human macrophages.
No takes yet. Share an insight, caveat, or question.
Verberk et al. (2024) conducted a case-control in Inherited long-chain fatty acid oxidation disorders (n=22). Inherited long-chain fatty acid oxidation disorders vs. Matched control subjects was evaluated on Monocyte and macrophage phenotype and function, and plasma cytokine levels. Patients with long-chain fatty acid oxidation disorders showed induced plasma IL-1β and IL-6 and enhanced monocyte CD206 and CD62L expression, but no major inflammatory or metabolic differences.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: